The presentation of positive clinical and preclinical data on fosgonimeton, a potential treatment for Alzheimer's and Parkinson's diseases, at a significant international conference could positively impact Athira Pharma's stock price in the short term. This is due to increased investor optimism about the drug's market potential and the company's future revenue prospects.